GlassScriptPhysician profile
Ihab Herraka
NPI 1174610018
$3,549.26
in general payments reported to CMS, 2019-2025
25 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.11 · 2020: $104 · 2021: $551 · 2022: $277 · 2023: $638 · 2024: $1,109 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,606.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,168.96 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.68 | 2021-2025 | Xifaxan, Plenvu, Relistor |
| Janssen Biotech, INC. | $339.34 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $263.27 | 2023-2025 | |
| Gilead Sciences, INC. | $205.30 | 2020-2025 | |
| Ardelyx, INC. | $161.87 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $146.86 | 2023-2025 | Entyvio |
| Genzyme Corporation | $120.11 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $113.86 | 2020-2024 | |
| Aimmune Therapeutics, INC. | $83.73 | 2024 | |
| Currax Pharmaceuticals LLC | $70.27 | 2021-2023 | Contrave |
| Medtronic, INC. | $67.06 | 2023 | Interstim, Pillcam |
| Celgene Corporation | $59.56 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $57.55 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $50.44 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $49.78 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $44.16 | 2021-2023 | Dificid |
| Vbi Vaccine (Delaware) INC. | $33.52 | 2022 | |
| Dynavax Technologies Corporation | $28.91 | 2019-2021 | |
| Redhill Biopharma INC. | $26.16 | 2024 | Talicia, Aemcolo |
| Lilly USA, LLC | $25.44 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $24.04 | 2025 | Iqirvo |
| Ucb, INC. | $20.39 | 2021 | |
| Lucid Diagnostics INC. | $18.92 | 2023 | |
| Dentsply Ih Ab | $13.08 | 2024 | Navina Rectal Catheter Set Regular |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ihab Herraka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.